Jacobs Levy Equity Management’s Assembly Biosciences ASMB Stock Holding History

Jacobs Levy Equity Management’s Portfolio ASMB Stock Details ASMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-16,713	Closed	-$698K	–	969
2021 Q3	$698K	Sell	16,713 -1,662	-9%	-$69.7K	﹤0.01%	816
2021 Q2	$856K	Sell	18,375 -3,035	-14%	-$150K	0.01%	769
2021 Q1	$1.18M	Buy	21,410 +6,998	+49%	+$464K	0.01%	703
2020 Q4	$1.05M	Buy	+14,412	New	+$1.69M	0.01%	713
2020 Q1	–	Sell	-1,562	Closed	-$383K	–	1002
2019 Q4	$383K	Buy	1,562 +448	+40%	+$82.5K	﹤0.01%	819
2019 Q3	$131K	Buy	+1,114	New	+$169K	﹤0.01%	878
2017 Q4	–	Sell	-1,632	Closed	-$684K	–	985
2017 Q3	$684K	Sell	1,632 -1,924	-54%	-$590K	0.01%	656
2017 Q2	$881K	Buy	3,556 +159	+5%	+$44.8K	0.02%	590
2017 Q1	$1.04M	Hold	3,397	–	–	0.02%	548
2016 Q4	$495K	Hold	3,397	–	–	0.01%	680
2016 Q3	$294K	Sell	3,397 -568	-14%	-$43.9K	0.01%	814
2016 Q2	$264K	Sell	3,965 -309	-7%	-$20.3K	0.01%	917
2016 Q1	$257K	Buy	+4,274	New	+$286K	0.01%	913

Other funds holding ASMB

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management's ASMB Position: Q4 2021 in Review

Jacobs Levy Equity Management sold out of Assembly Biosciences (ASMB) in Q4 2021, closing a stake of 16,713 shares — an estimated $698K sold.

Jacobs Levy Equity Management first reported a position in ASMB in Q1 2016 and held it in 13 quarters. The position peaked at $1.18M in Q1 2021. 62 funds tracked by Wall St. Rank hold ASMB as of Q4 2021.

Jacobs Levy Equity Management reported no remaining Assembly Biosciences position as of Q4 2021 after selling out during the quarter.
Jacobs Levy Equity Management sold 16,713 Assembly Biosciences shares in Q4 2021, an estimated $698K.
Jacobs Levy Equity Management first reported a position in Assembly Biosciences in Q1 2016 and held it in 13 quarters.
Jacobs Levy Equity Management's Assembly Biosciences position peaked at $1.18M in Q1 2021.
62 funds tracked by Wall St. Rank held Assembly Biosciences as of Q4 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2021, filed 14 Feb 2022.